The direct-acting antiviral glecaprevir/pibrentasvir (Mavyret) was highly effective and well tolerated in adults with acute ...

CHICAGO (Reuters) - Two standard treatments for hepatitis C work equally well at knocking down the virus for most patients, U.S. researchers reported on Wednesday. The findings, from a 3,000-patient ...

In 2005, Nick Voyles was diagnosed with hepatitis C after being released from five years of incarceration. A nurse told him he had only six months to live. He was prescribed a drug cocktail, a ...

(Reuters) - A trio of oral medicines from Abbott Laboratories Inc to treat hepatitis C produced unprecedented cure rates in patients who had failed to benefit from standard treatment, as well as very ...

Pharmasset, Inc. has received fast-track designation from the U.S. Food and Drug Administration for R7128 for the treatment of chronic hepatitis C virus infection.Pharmasset, Inc. (Nasdaq: VRUS) has ...

There's a new drug regimen being touted as a potential cure for a dangerous liver virus that causes hepatitis C. But it costs $84,000 -- or $1,000 a pill. And that price tag is prompting outrage from ...

The introduction of AbbVie’s hepatitis C drugs in 2014 forced Gilead’s hand in the fight for market dominance in hepatitis C.

It’s been almost a year since federal regulators approved a new hepatitis C treatment that costs about $1,000 per pill. But time hasn’t done much to ease concerns of state officials who worry about ...

Any national campaign to eliminate hepatitis C, an insidious virus that kills tens of thousands of Americans a year, would almost certainly involve prisons. One in 7 state inmates are believed to be ...

WASHINGTON (AP) — Doctors may soon have two new drug options for patients with hepatitis C, just as the liver-destroying virus becomes a major public health concern for millions of baby boomers. The ...

WHO releases new framework to tackle drug resistance to HIV, hepatitis B and C, and STIs: Geneva Thursday, November 27, 2025, 10:00 Hrs [IST] The World Health Organization (WHO) h ...

NEW YORK (AP) — Drugmaker Bristol-Myers Squibb Co. has scrapped a potential hepatitis C treatment after a patient participating in a test of the drug died of heart failure. The New York company said ...